Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Robert Ballard

Sleep Medicine Littleton, CO Medical Doctor

NPI 1255424347 CMS profile 147715

15 W Dry Creek Cir, Littleton, CO 80120

Open in the dashboard

General payments

$2,930

169 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Robert Ballard of Littleton, CO is reported in the CMS Open Payments database as having received $2,930 across 169 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 68th percentile of Sleep Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $124 2
2023 General $20 1
2022 General $547 27
2021 General $590 30
2020 General $273 15
2019 General $1,377 94

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Ballard
  • Sleep Medicine median
  • Middle half of Sleep Medicine
  • National median

In program year 2025, general payments to Robert Ballard were reported at $124. Among 670 Sleep Medicine profiles paid that year, the median was $439 and the middle half received between $127 and $1,274.

Show as a table
Year Robert Ballard Sleep Medicine median Middle half National median
2019 $1,377 $185 $66–$736 $163
2020 $273 $149 $46–$504 $114
2021 $590 $191 $62–$750 $132
2022 $547 $246 $92–$972 $149
2023 $20 $321 $119–$1,033 $160
2024 $0 $393 $111–$1,207 $164
2025 $124 $439 $127–$1,274 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Harmony Biosciences LLC $501 20 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $449 23 payments
  3. AstraZeneca Pharmaceuticals LP $408 25 payments
  4. GlaxoSmithKline, LLC. $334 25 payments
  5. Grifols USA, LLC $212 20 payments
  6. United Therapeutics Corporation $107 6 payments
  7. Sunovion Pharmaceuticals Inc. $102 5 payments
  8. Mylan Specialty L.P. $82 5 payments
  9. Jazz Pharmaceuticals Inc. $78 4 payments
  10. OptiNose US, Inc. $70 4 payments
  11. Other $588 32 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,785 167 payments
  2. Education $145 2 payments
Products named General payments · program years 2019–2025
  1. Wakix $401 19 payments
  2. SPIRIVA RESPIMAT $336 19 payments
  3. Prolastin-C Liquid $212 20 payments
  4. FASENRA $167 10 payments
  5. TRELEGY ELLIPTA $147 9 payments
  6. OFEV $141 5 payments
  7. SYMBICORT $111 7 payments
  8. STIOLTO RESPIMAT $108 5 payments
  9. TYVASO $107 6 payments
  10. LONHALA MAGNAIR $102 5 payments
  11. Other $1,312 79 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

185

Median for Internal Medicine: 777

Drug cost

$84,452

Median for Internal Medicine: $73,373

Branded share of claims

81.1%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 63 $48,585
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 21 $19,158
Spiriva Respimat Tiotropium Bromide Brand 11 $14,690
Pramipexole Dihydrochloride Pramipexole Di-Hcl Brand 39 $1,066
Gabapentin Generic 22 $444
Albuterol Sulfate Hfa Albuterol Sulfate Brand 16 $376
Clonazepam Generic 13 $133

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$108,501

Medicare's payments for the services billed

Medicare patients

328

Average age 74

Services billed

595

158 women, 170 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Arthritis 50%
Ischemic heart disease 37%
Atrial fibrillation 27%
Diabetes 25%
Chronic kidney disease 24%
Depression 24%
Heart failure 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

169 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sleep Medicine in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record